Salute e Benessere

Lexogen achieves ISO 13485:2016 quality management certification

"Obtaining ISO 13485 certification is a significant milestone for Lexogen," says Stéphane Barges, Chief Executive Officer at Lexogen. "This achievement highlights our unwavering commitment to providing cutting-edge biotechnology solutions, built considering the needs of our customers, that meet the highest quality standards. It reinforces our position as a trusted partner in the industry and demonstrates our dedication to customer satisfaction." " Obtaining ISO 13485…

HMNC Brain Health to Participate in the Psychedelic Science Conference 2023 and…

Psychedelic Science Conference 2023 HMNC to participate in the Psychedelic Science Conference 2023, at the Colorado Convention Center in Denver, Colorado from June 21-23, 2023. Dr. Daniel Gehrlach, HMNC's Associate Director – Biomarkers, will take part in the panel ' AI and Computational Approaches to Drug Discovery ', at 12:00pm MDT on June 22, 2023 in the Mile High 3 room. To register for the conference please click here . H.C. Wainwright & Co. 4 thAnnual Neuropsychiatry...

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene…

~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline and clinical benefits relative to natural history of the disease ~~ Neurofilament Light Chain (NfL) in cerebrospinal fluid (CSF) was below baseline at 24 months in patients treated with the low-dose of AMT-130 and declining towards baseline at 12 months in patients treated with the high-dose of AMT-130 ~ ~ Suppression of CSF...

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to…

Co-founded by radiopharmaceutical veterans Roy Larsen, Ph.D., and Øyvind Bruland, M.D., in collaboration with F-Prime Capital and Radforsk, with backing from Omega Funds Co-founded by radiopharmaceutical veteransRoy Larsen, Ph.D., and Øyvind Bruland, M.D., in collaboration with F-Prime Capital and Radforsk, with backing from Omega Funds Led by an experienced team of industry and radiopharmaceutical experts, including founding CEOEmanuele Ostuni, Ph.D., ChairmanTed W. Love, M.D...

Jonathan Milner issues Open Letter to shareholders of Abcam plc

Jonathan Milner issues Open Letter to shareholders of Abcam plcResponds to Company's assertions in its statementon 20 June 2023Outlines Abcam's lack of focus and Milner's detailed plans to restore the Company's financials, accountability and executional discipline Urges all ADS shareholders to vote 'FOR' all of Milner's proposals on the BLUE proxy card by10am EST on 6 July 2023ahead of the Extraordinary General Meeting on...

Dataintelo releases comprehensive Global Mobile C-arm Systems Market report…

Download PDF Sample here: https://dataintelo.com/request-sample/?reportId=13264 Download PDF Sample here:https://dataintelo.com/request-sample/?reportId=13264 The end users covered in the report include Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research Institutes. The regional analysis of the Global Mobile C-arm Systems Market examines the market inNorth America,Latin America,Europe,Asia Pacific,Middle East&Africa. This segmentation...

FORESEE PHARMACEUTICALS PRESENTED POSTER ON MMP-12 INHBITOR, FP-020, IN GENETIC…

"We are very enthusiastic about the data in this poster, as it strongly validates MMP-12 as a potential target for cardiac sarcoidosis and strongly corroborates the evidence amassed to date, both by our group and collaborators, supporting a potentially pivotal role of MMP-12 biology in the pathophysiology of sarcoidosis and other diseases with immune-fibrotic and granulomatous components". "FP-020 is one of the most efficacious drugs we have tested in our sarcoidosis disease…

Dataintelo Releases Comprehensive Report on Global Wireless Electronic Health…

Download PDF Sample here: https://dataintelo.com/request-sample/?reportId=13886 Download PDF Sample here:https://dataintelo.com/request-sample/?reportId=13886 The report categorizes the global wireless EHR market by type into 3G/Commercial Cellular, Bluetooth, Radio Frequency Identification (RFID), Satellites, Sensors, WiMAX, Wireless LANs, and Zigbee. This segmentation allows for a better understanding of the market dynamics and helps stakeholders identify potential growth areas...

Dataintelo Releases Comprehensive Report on Global Telemonitoring System Market…

Download PDF Sample here: https://dataintelo.com/request-sample/?reportId=13870 Download PDF Sample here:https://dataintelo.com/request-sample/?reportId=13870 One of the key aspects of the report is its in-depth analysis of the different types of telemonitoring systems available in the market. These include COPD, glucose level, blood pressure, cardiac monitoring systems, and others. The study provides valuable insights into the growth trends and opportunities in each of these segments,...

Cosmetic Implants Market to be Worth $21.2 Billion by 2030: Grand View Research…

Key Industry Insights & Findings from the report: Key Industry Insights & Findings from the report: Read 180-page market research report, "Cosmetic Implants Market Size, Share & Trends Analysis Report By Application (Dental Implants, Breast Implants, Facial Implants), By Material (Polymers, Ceramics, Metal, Biological Material), By Region, And Segment Forecasts, 2023 - 2030", published by Grand View Research. Cosmetic Implants Market Growth & Trends American...

Veterinary API Market worth $7.1 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91801752 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=91801752 Browse in-depth TOC on "Veterinary API Market" 150 - Tables 60 - Figures 350 - Pages Veterinary API Market Scope: In this report, the Veterinary API Market is segmented based on API Type, Synthesis Type, Route of Administration, Animal Type, and region. "Oral...

Telix to Expand Late-Stage Urologic Pipeline with Acquisition of Lightpoint…

This highly strategic and synergistic transaction broadly strengthens Telix's capabilities in deploying molecular imaging in the surgical setting. The acquisition will further enhance and differentiate Telix's innovation position and product depth in urology by enabling targeted radiation to be harnessed across the entire continuum of cancer patient care, from initial diagnosis and staging, to surgical intervention and therapeutic use. This highly strategic and synergistic transaction broadly...

Dataintelo Publishes Comprehensive Report on Global Smart Biosensor Market as…

Download PDF Sample here: https://dataintelo.com/request-sample/?reportId=15576 Download PDF Sample here:https://dataintelo.com/request-sample/?reportId=15576 The Dataintelo report on the global smart biosensor market highlights the key factors that are expected to drive the growth of the market in the coming years. These factors include the increasing prevalence of chronic diseases, such as diabetes and cardiovascular disorders, which necessitate regular monitoring and management of...

North America Banks on Technological Advancements in Clinical Laboratory…

Order your copy of the Free Sample of "Clinical Laboratory Industry Data Book - Clinical Laboratory Tests and Clinical Laboratory Service Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030" Data Book, published by Grand View Research Order your copy of the Free Sample of " Clinical Laboratory Industry Data Book - Clinical Laboratory Tests and Clinical Laboratory Service Market Size, Share, Trends Analysis, And Segment Forecasts, 2023 - 2030 " Data Book…

Versameb Appoints Professor Roger Dmochowski as Chief Medical Officer

BASEL, Switzerland, June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer with immediate effect. BASEL, Switzerland , June 21, 2023 /PRNewswire/ -- Versameb AG ("Versameb"), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is…

Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food…

The sNDA submission is based on the full data set from the Phase 3 NefIgArd clinical trial, a randomized, double-blind, multicenter study which assessed the efficacy and safety of TARPEYO (developed under the project name Nefecon®) dosed at 16 mg once daily versus placebo on a background of optimized RASi therapy in adult patients with primary IgAN. The trial met its primary endpoint, with TARPEYO demonstrating a highly statistically significant benefit over placebo (p value < 0.0001) in…

Dataintelo Releases Comprehensive Report on Global Oral Cancer Diagnostic…

Download PDF Sample here: https://dataintelo.com/request-sample/?reportId=15573 Download PDF Sample here:https://dataintelo.com/request-sample/?reportId=15573 As per the regional analysis, the report segments the market intoNorth America,Latin America,Europe,Asia Pacific, andMiddle East&Africa, with detailed country-wise data available for each region. The report also includes a competitive landscape analysis, presenting an overview of the key market players and...

Mediso receives FDA approval for InterView™ nuclear medicine image processing…

The vendor independent InterView™ software offers a complete solution for image visualization, post-processing and reporting specifically adapted for the routine nuclear medicine and molecular imaging workflow. Workflows and specialized tools cover the most common nuclear medicine studies including bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung. Fast and standardized reporting is available for all nuclear medicine procedures...

570 000 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 21 JUNE 2023 at 10.15 EEST 570 000Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 570 000 A shares have been converted into 570 000 B shares. The conversion has been entered into the Trade Register on 21 June 2023.The total number of shares in Orion Corporation is 141,134,278 which,...

IBT continues to recruit prematurely born infants to The Connection Study…

In accordance with the study protocol, the independent Data Monitoring Committee (DMC) has performed the final planned safety analysis of Infant Bacterial Therapeutics AB (IBT) drug candidate IBP-9414. The analysis was based on data from 1,403 babies in the ongoing Phase III study.The recommendation from the DMC is that recruitment can continue as planned, in accordance with the approved study protocol. The study was initiated in July 2019 and is ongoing in the USA, Bulgaria, France,...

EQT Private Equity to sell Ellab, following transformation into a leading…

EQT Private Equity acquired Ellab in September 2019 with a vision to accelerate the Company's growth journey by solidifying its core offering within validation solutions, while expanding into monitoring solutions and field services & consulting. Today, Ellab has transformed into a full solution provider, while tripling its revenues, EBITDA and employee base. It counts all the top 20 biotech companies and all the top 40 pharmaceutical companies globally as clients. EQT Private Equity…

Novo Holdings to acquire Ellab

Initially established as a family-owned business in 1949 in Denmark, Ellab began its journey by developing temperature sensors for the food industry. Today, Ellab has transformed into a full-suite provider of validation and monitoring solutions and services for the biotech and pharmaceutical industries, serving a blue-chip customer base globally. Novo Holdings will support the continued growth of Ellab, building on the impressive long-standing track-record, by utilising its industry network and…

Essential Pharma appoints Lee Morley as Non-Executive Director to the Board

Essential Pharma appoints Lee Morleyas Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21June2023– Essential Pharma, an international specialty pharma group focused on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas, announces the appointment of Lee Morley as Non-Executive Director to the Board.Lee brings more than 30 years of experience as a leader...

UNION therapeutics announces positive topline results from the OSIRIS…

The conclusion on the doses explored is consistent with the findings from the subsequent IASOS Phase 2b dose-finding study in psoriasis recently reported. The target product profile of oral orismilast was confirmed including the well-established favorable safety profile of PDE4 inhibition. The conclusion on the doses explored is consistent with the findings from the subsequent IASOS Phase2bdose-finding study in psoriasis recently reported. The target product profile of oral orismilast was...

Altri Comunicati